AVXL
HEALTHCAREAnavex Life Sciences Corporation
$3.34-0.02 (-0.60%)LIVE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving AVXL Today?
No stock-specific AI insight has been generated for AVXL yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.61$13.99
$3.34
Fundamentals
Market Cap$289M
P/E Ratio—
EPS$-0.46
Dividend Yield—
Dividend / Share—
ROE-0.3%
Profit Margin—
Debt / Equity—
Trading
Volume1.1M
Avg Volume (10D)—
Shares Outstanding92.7M
AVXL News
20 articles- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in FocusAdvfn·May 6, 2026
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive OfficerYahoo Finance·May 6, 2026
- AMD downgraded, Airbnb upgraded: Wall Street's top analyst callsYahoo Finance·May 4, 2026
- Exploring Three High Growth Tech Stocks In The US MarketYahoo Finance·Apr 29, 2026
- What Makes Anavex Life Sciences (AVXL) One of the Best Shorted Penny StocksYahoo Finance·Apr 26, 2026
- Anavex Life Sciences Teases New Pivotal Blarcamesine Trials, Maps Regulatory Path at Needham ConferenceMarketbeat·Apr 15, 2026
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s DiseaseYahoo Finance·Apr 14, 2026
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare ConferenceYahoo Finance·Apr 7, 2026
- 3 Promising Penny Stocks With At Least $200M Market CapYahoo Finance·Apr 2, 2026
- High Growth Tech Stocks in US for March 2026Yahoo Finance·Mar 31, 2026
- Anavex Life Sciences Provides Comprehensive Regulatory UpdateYahoo Finance·Mar 30, 2026
- Anavex Life Sciences Stock Is Deeply Oversold. Should You Buy the Dip?Barchart·Mar 26, 2026
- Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn SituationYahoo Finance·Mar 26, 2026
- Top Midday DeclinersYahoo Finance·Mar 25, 2026
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s DiseaseYahoo Finance·Mar 25, 2026
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s DiseaseYahoo Finance·Mar 23, 2026
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s DiseaseYahoo Finance·Mar 20, 2026
- Is AC Immune (ACIU) Outperforming Other Medical Stocks This Year?Yahoo Finance·Mar 18, 2026
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 ConferenceYahoo Finance·Mar 17, 2026
- Anavex Life Sciences Touts Oral Alzheimer’s Drug Blarcamesine Data, Cash Runway at Healthcare ConferenceMarketbeat·Mar 5, 2026
All 20 articles loaded
Price Data
Open$3.45
Previous Close$3.36
Day High$3.49
Day Low$3.33
52 Week High$13.99
52 Week Low$2.61
52-Week Range
$2.61$13.99
$3.34
Fundamentals
Market Cap$289M
P/E Ratio—
EPS$-0.46
Dividend Yield—
Dividend / Share—
ROE-0.3%
Profit Margin—
Debt / Equity—
Trading
Volume1.1M
Avg Volume (10D)—
Shares Outstanding92.7M
About Anavex Life Sciences Corporation
Anavex Life Sciences Corp. The company is headquartered in New York, New York.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—